In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
754: The Global Mental Health Toll Of Climate Change | Capturing DNA From 800 Lakes In One Day
753: Clean Energy Transition Progress | Avian Flu In Cattle And Humans Has Scientists Concerned
752: A Cheer For The Physics Of Baseball
752: Carbon Cost Of Urban Gardens And Commercial Farms | Why There's No Superbloom This Year
751: Inside The Race To Save Honeybees From Parasitic Mites
750: The Brain’s Glial Cells Might Be As Important As Neurons
749: Limits On ‘Forever Chemicals’ In Drinking Water | An Important Winter Home For Bugs | Eclipse Drumroll
748: Investigating Animal Deaths At The National Zoo
745: Eating More Oysters Helps Us—And The Chesapeake Bay
747: How Trees Keep D.C. And Baltimore Cool
744: Predicting Heart Disease From Chest X-Rays With AI | Storing New Memories During Sleep
746: Recipient Of Pig Kidney Transplant Recovering | Answering Your Questions About April 8 Eclipse
743: Our Inevitable Cosmic Apocalypse
742: The Complicated Truths About Offshore Wind And Right Whales
740: ‘3 Body Problem’ And The Laws Of Physics | In Defense Of ‘Out Of Place’ Plants
739: Baltimore Bridge Collapse | Mapping How Viruses Jump Between Species
738: The Legacy Of Primatologist Frans de Waal
737: The ‘Asteroid Hunter’ Leading The OSIRIS-REx Mission
736: Swimming Sea Lions Teach Engineers About Fluid Dynamics
Create your
podcast in
minutes
It is Free
The Modern West
Voices of Misery Podcast
House of Whimsical Terror
Dairyland Frights
Stuff You Should Know
Timcast IRL